Potential risks of metformin in transplant patients

American Journal of Transplantation

Volumn 12, Issue 3, 2012, Pages 795-

  Larsen, J L ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; INSULIN; METFORMIN;

DIABETES MELLITUS; DRUG CHOICE; DRUG EFFICACY; HOSPITAL PATIENT; HUMAN; HYPERGLYCEMIA; KIDNEY FAILURE; LACTIC ACIDOSIS; LETTER; MEDICAL DECISION MAKING; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SEPSIS; TRANSPLANTATION;

HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; ORGAN TRANSPLANTATION;

EID: 84857653049     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03921.x     Document Type: Letter

References (1)

1. Adnan S,. Should metformin be our antiglycemic agent of choice posttransplantation? Am J Transplant 2011; 11: 1376-1381.